Study of Ferritin in Immune-Related Side Effects
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how a blood marker called ferritin relates to side effects from immunotherapy or other cancer treatments. It may help doctors predict and manage those side effects better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a confirmed solid tumor or acute leukemia.
- You are about to receive immunotherapy, targeted therapy, or chemotherapy.
- Your blood counts (neutrophils, lymphocytes, platelets, hemoglobin) are within a certain range.
- Your liver, kidney, and lung function meet certain thresholds.
- You do not have an active autoimmune disease that needs treatment, and you have not had steroids within 2 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
This Phase 3 study tests whether giving ferric carboxymaltose (an IV iron treatment) helps people with advanced stomach or stomach–esophagus cancer and iron-deficiency anemia. The goal is to improve safety and how well the standard first-line cancer treatment works.
This study collects blood, stool, and tissue samples from people who have had side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer). It aims to learn more about these side effects, so doctors can better manage them in the future.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study looks at whether your blood vitamin D level is linked to hormone-related side effects caused by immune checkpoint cancer drugs. It may help doctors better predict who is at risk and how to monitor patients during treatment.
This trial tests a combination of two drugs: peginterferon α-2b (an immune-boosting drug) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). They hope the combo might work better for people with advanced solid tumors that haven't responded to other treatments.
Hear when a new Immune-related Adverse Event trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.